Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease,…
An institutional-grade, numbers-driven thesis on INSM — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Insmed Incorporated (INSM) 61/100 with a 12-month base-case forecast of $196.71 — +50.0% versus the current price of $131.10. Insmed Incorporated trades at $131.10 in the Healthcare sector, with a market capitalisation of $28.42B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for INSM is $196.71, implying +50.0% versus the current price. The model's 12-month scenario range runs from $122.81 (bear) to $159.96 (bull), with a base case of $135.92.
On the fundamentals, Insmed shows a P/E of -31.9, trailing revenue of $606.4M, revenue growth of +66.7% YoY. This page also tracks INSM's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
INSM currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $196.71 implies +50.0% from $131.10. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for INSM is $196.71, about +50.0% versus the latest price of $131.10. Consensus is based on 35 analysts.
TradersQuant's 12-month model forecast for INSM is a base case of $135.92, ranging from $122.81 (bear) to $159.96 (bull), an expected return of +3.7%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for INSM over the next 12 months is $135.92 in the base case (bear $122.81, bull $159.96), versus today's price of $131.10. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for INSM — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates INSM's fair value at $196.71, implying +50.0% of expected upside versus the current price.
Insmed does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
